You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》花旗指和譽(02256.HK)目前估值偏低 升目標價至17.5元籲「買入」
阿思達克 08-11 11:13
花旗研究報告指,認為和譽(02256.HK)現估值偏低,基於其2款晚期候選藥pimicotinib與irpagratinib都具高度確定性,且差異化創新管線有望實現對外授權。該行預期irpagratinib二線肝細胞癌三期臨床試驗的成功率極高,其估值應被納入考量因素。 另外,該行認為和譽在2025及2026年將會有關鍵催化劑出現,關注其pimicotinib上市審批及商業化表現、irpagratinib三期數據公布,以及ABSK043及ABSK061等多項候選藥物的數據更新,和潛在的商業合作。 該行將和譽2026年收入預測由2.89億元人民幣下調至2.8億元人民幣,每股虧損預測由0.38元人民幣調整至0.39元人民幣,並預期2027年收入及每股虧損分別為4.52億及0.34元人民幣;維持「買入」評級,目標價由10港元升至17.5港元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account